Group 1 - The company has received feedback from its internal rectification team confirming that the current trial progress is below expectations, and its subsidiary Tianjin Weiming is expected to be unable to resume normal production and operations within three months [1][2] - As a result of the above situation, the company's stock will be subject to "other risk warnings," changing its name from "Weiming Pharmaceutical" to "ST Weiming," with the stock code remaining "002581" and the daily price fluctuation limit changing from 10% to 5% [1][2] - The suspension of production and sales by Tianjin Weiming, which is a significant subsidiary responsible for the production and sales of interferon drugs, has a substantial impact on the company's operations, accounting for 60.09% of the company's revenue and 9.8% of the consolidated net profit [1][2] Group 2 - The company's board of directors acknowledges the adverse effects of the situation and plans to take effective measures to mitigate the impact, including promoting product sales in other markets and increasing efforts in market development and new product development [2] - Other subsidiaries of the company are operating normally and maintaining production capabilities, while the company aims to optimize management, reduce expenses, control costs, and enhance business profitability to ensure stable operations [3] - During the period of other risk warnings, the company will accept investor inquiries through phone and email, ensuring timely responses while adhering to insider information confidentiality regulations [3]

未名医药已连续三年亏损 作为未名医药控股子公司，天津未名主要从事人干扰素药品的生产与销售。对整个未名医药来说，天津 未名分量不轻，天津未名2024年实现营收2.17亿元，占未名医药同期营收的60.09%，天津未名2024年亏 损1400.37万元，正如未名医药在公告中披露，"天津未名为公司重要子公司，本次暂停生产、销售事项 对公司生产经营产生重要影响。" 这已经不是天津未名首次出现药品质量问题。今年3月，江西省联采办发布公告，药监部门对天津未名 生产的α2b喷雾剂进行抽检，检验结果为"生物学活性不符合规定"。按照《干扰素省际联盟集中带量采 购文件（文件编号：JX-YP2023-01）》等相关要求，各地（市）医疗保障局应通知辖区内医疗机构暂 停采购天津未名生产的人干扰素α2b喷雾剂，中选企业封存召回，恢复采购时间另行通知。西藏、内蒙 古随后暂停了天津未名人干扰素α2b喷雾剂的交易资格。 未名医药在2024年年报中也披露，上海市药品监督管理局对天津未名生产的1批"人干扰素α2b喷雾剂"进 行抽检，检验结果为"生物学活性不符合规定"。天津未名针对该批次检验结果向原药品承检单位申请复 验，复验结果尚未出具。未名医药决 ...